FXYD3 is overexpressed in pancreatic ductal adenocarcinoma and influences pancreatic cancer cell growth

Hany Kayed, Jörg Kleeff, Armin Kolb, Knut Ketterer, Shereen Keleg, Klaus Felix, Thomas Giese, Roland Penzel, Hanswalter Zentgraf, Markus W. Büchler, Murray Korc, Helmut Friess

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

The expression and localization of FXYD domain containing ion transport regulator 3 (FXYD3), a transmembrane protein that acts as a chloride channel or chloride channel regulator, was analyzed in pancreatic tissues derived from donors and patients suffering from chronic pancreatitis (CP) or pancreatic ductal adenocarcinoma (PDAC) as well as in pancreatic cancer cells using QRT-PCR, laser-capture microdissection and microarray analysis, in situ hybridization and immunohistochemistry. FXYD3 antisense expressing T3M4 pancreatic cancer cells were generated and compared to control cells using anchorage-dependent and independent growth assays, and xenotransplantation into nude mice. FXYD3 mRNA levels were 3.4-fold increased in PDAC tissues compared to donor specimens (p = 0.006), and 3.9-fold increased in microdissected cancer cells compared to normal pancreatic ductal cells (p = 0.02). FXYD3 was localized in the tubular complexes and PanIN lesions of both CP and PDAC, as well as in pancreatic cancer cells. Downregulation of FXYD3 by stable antisense transfection increased significantly the doubling time of T3M4 pancreatic cancer cells from 44 ± 2 hr to 55 ± 12 hr (p = 0.02). Nude mice transplanted with antisense transfected cells displayed a significant increase in tumor doubling time from 3.3 days ± 1.0 to 4.3 days ± 0.43 (p = 0.058). Anchorage-independent growth and sensitivity to 5-fluorouracil, gemcitabine and cisplatin as well as to MgCl2 were not dependent on the level of FXYD3 expression. In conclusion, overexpression of FXYD3 in pancreatic cancer may contribute to the proliferative activity of this malignancy.

Original languageEnglish (US)
Pages (from-to)43-54
Number of pages12
JournalInternational Journal of Cancer
Volume118
Issue number1
DOIs
StatePublished - Jan 1 2006

Fingerprint

Pancreatic Neoplasms
Adenocarcinoma
Growth
Chloride Channels
Chronic Pancreatitis
gemcitabine
Nude Mice
Tissue Donors
Laser Capture Microdissection
Neoplasms
Heterologous Transplantation
Magnesium Chloride
Ion Transport
Microarray Analysis
Fluorouracil
Cisplatin
In Situ Hybridization
Transfection
Down-Regulation
Immunohistochemistry

Keywords

  • Chemotherapy
  • Chloride channel
  • Expression profiling
  • Pancreatic cancer
  • TGFβ

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

FXYD3 is overexpressed in pancreatic ductal adenocarcinoma and influences pancreatic cancer cell growth. / Kayed, Hany; Kleeff, Jörg; Kolb, Armin; Ketterer, Knut; Keleg, Shereen; Felix, Klaus; Giese, Thomas; Penzel, Roland; Zentgraf, Hanswalter; Büchler, Markus W.; Korc, Murray; Friess, Helmut.

In: International Journal of Cancer, Vol. 118, No. 1, 01.01.2006, p. 43-54.

Research output: Contribution to journalArticle

Kayed, H, Kleeff, J, Kolb, A, Ketterer, K, Keleg, S, Felix, K, Giese, T, Penzel, R, Zentgraf, H, Büchler, MW, Korc, M & Friess, H 2006, 'FXYD3 is overexpressed in pancreatic ductal adenocarcinoma and influences pancreatic cancer cell growth', International Journal of Cancer, vol. 118, no. 1, pp. 43-54. https://doi.org/10.1002/ijc.21257
Kayed, Hany ; Kleeff, Jörg ; Kolb, Armin ; Ketterer, Knut ; Keleg, Shereen ; Felix, Klaus ; Giese, Thomas ; Penzel, Roland ; Zentgraf, Hanswalter ; Büchler, Markus W. ; Korc, Murray ; Friess, Helmut. / FXYD3 is overexpressed in pancreatic ductal adenocarcinoma and influences pancreatic cancer cell growth. In: International Journal of Cancer. 2006 ; Vol. 118, No. 1. pp. 43-54.
@article{1d625fbdeb4c44ccbcab86a5b48dc844,
title = "FXYD3 is overexpressed in pancreatic ductal adenocarcinoma and influences pancreatic cancer cell growth",
abstract = "The expression and localization of FXYD domain containing ion transport regulator 3 (FXYD3), a transmembrane protein that acts as a chloride channel or chloride channel regulator, was analyzed in pancreatic tissues derived from donors and patients suffering from chronic pancreatitis (CP) or pancreatic ductal adenocarcinoma (PDAC) as well as in pancreatic cancer cells using QRT-PCR, laser-capture microdissection and microarray analysis, in situ hybridization and immunohistochemistry. FXYD3 antisense expressing T3M4 pancreatic cancer cells were generated and compared to control cells using anchorage-dependent and independent growth assays, and xenotransplantation into nude mice. FXYD3 mRNA levels were 3.4-fold increased in PDAC tissues compared to donor specimens (p = 0.006), and 3.9-fold increased in microdissected cancer cells compared to normal pancreatic ductal cells (p = 0.02). FXYD3 was localized in the tubular complexes and PanIN lesions of both CP and PDAC, as well as in pancreatic cancer cells. Downregulation of FXYD3 by stable antisense transfection increased significantly the doubling time of T3M4 pancreatic cancer cells from 44 ± 2 hr to 55 ± 12 hr (p = 0.02). Nude mice transplanted with antisense transfected cells displayed a significant increase in tumor doubling time from 3.3 days ± 1.0 to 4.3 days ± 0.43 (p = 0.058). Anchorage-independent growth and sensitivity to 5-fluorouracil, gemcitabine and cisplatin as well as to MgCl2 were not dependent on the level of FXYD3 expression. In conclusion, overexpression of FXYD3 in pancreatic cancer may contribute to the proliferative activity of this malignancy.",
keywords = "Chemotherapy, Chloride channel, Expression profiling, Pancreatic cancer, TGFβ",
author = "Hany Kayed and J{\"o}rg Kleeff and Armin Kolb and Knut Ketterer and Shereen Keleg and Klaus Felix and Thomas Giese and Roland Penzel and Hanswalter Zentgraf and B{\"u}chler, {Markus W.} and Murray Korc and Helmut Friess",
year = "2006",
month = "1",
day = "1",
doi = "10.1002/ijc.21257",
language = "English (US)",
volume = "118",
pages = "43--54",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - FXYD3 is overexpressed in pancreatic ductal adenocarcinoma and influences pancreatic cancer cell growth

AU - Kayed, Hany

AU - Kleeff, Jörg

AU - Kolb, Armin

AU - Ketterer, Knut

AU - Keleg, Shereen

AU - Felix, Klaus

AU - Giese, Thomas

AU - Penzel, Roland

AU - Zentgraf, Hanswalter

AU - Büchler, Markus W.

AU - Korc, Murray

AU - Friess, Helmut

PY - 2006/1/1

Y1 - 2006/1/1

N2 - The expression and localization of FXYD domain containing ion transport regulator 3 (FXYD3), a transmembrane protein that acts as a chloride channel or chloride channel regulator, was analyzed in pancreatic tissues derived from donors and patients suffering from chronic pancreatitis (CP) or pancreatic ductal adenocarcinoma (PDAC) as well as in pancreatic cancer cells using QRT-PCR, laser-capture microdissection and microarray analysis, in situ hybridization and immunohistochemistry. FXYD3 antisense expressing T3M4 pancreatic cancer cells were generated and compared to control cells using anchorage-dependent and independent growth assays, and xenotransplantation into nude mice. FXYD3 mRNA levels were 3.4-fold increased in PDAC tissues compared to donor specimens (p = 0.006), and 3.9-fold increased in microdissected cancer cells compared to normal pancreatic ductal cells (p = 0.02). FXYD3 was localized in the tubular complexes and PanIN lesions of both CP and PDAC, as well as in pancreatic cancer cells. Downregulation of FXYD3 by stable antisense transfection increased significantly the doubling time of T3M4 pancreatic cancer cells from 44 ± 2 hr to 55 ± 12 hr (p = 0.02). Nude mice transplanted with antisense transfected cells displayed a significant increase in tumor doubling time from 3.3 days ± 1.0 to 4.3 days ± 0.43 (p = 0.058). Anchorage-independent growth and sensitivity to 5-fluorouracil, gemcitabine and cisplatin as well as to MgCl2 were not dependent on the level of FXYD3 expression. In conclusion, overexpression of FXYD3 in pancreatic cancer may contribute to the proliferative activity of this malignancy.

AB - The expression and localization of FXYD domain containing ion transport regulator 3 (FXYD3), a transmembrane protein that acts as a chloride channel or chloride channel regulator, was analyzed in pancreatic tissues derived from donors and patients suffering from chronic pancreatitis (CP) or pancreatic ductal adenocarcinoma (PDAC) as well as in pancreatic cancer cells using QRT-PCR, laser-capture microdissection and microarray analysis, in situ hybridization and immunohistochemistry. FXYD3 antisense expressing T3M4 pancreatic cancer cells were generated and compared to control cells using anchorage-dependent and independent growth assays, and xenotransplantation into nude mice. FXYD3 mRNA levels were 3.4-fold increased in PDAC tissues compared to donor specimens (p = 0.006), and 3.9-fold increased in microdissected cancer cells compared to normal pancreatic ductal cells (p = 0.02). FXYD3 was localized in the tubular complexes and PanIN lesions of both CP and PDAC, as well as in pancreatic cancer cells. Downregulation of FXYD3 by stable antisense transfection increased significantly the doubling time of T3M4 pancreatic cancer cells from 44 ± 2 hr to 55 ± 12 hr (p = 0.02). Nude mice transplanted with antisense transfected cells displayed a significant increase in tumor doubling time from 3.3 days ± 1.0 to 4.3 days ± 0.43 (p = 0.058). Anchorage-independent growth and sensitivity to 5-fluorouracil, gemcitabine and cisplatin as well as to MgCl2 were not dependent on the level of FXYD3 expression. In conclusion, overexpression of FXYD3 in pancreatic cancer may contribute to the proliferative activity of this malignancy.

KW - Chemotherapy

KW - Chloride channel

KW - Expression profiling

KW - Pancreatic cancer

KW - TGFβ

UR - http://www.scopus.com/inward/record.url?scp=27944509575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27944509575&partnerID=8YFLogxK

U2 - 10.1002/ijc.21257

DO - 10.1002/ijc.21257

M3 - Article

C2 - 16003754

AN - SCOPUS:27944509575

VL - 118

SP - 43

EP - 54

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 1

ER -